Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Placebo-Controlled, Sequential Group, Single Dose, Dose-Escalation Study to Evaluate the Safety and PK of ETI-204

This study has been completed.
Information provided by (Responsible Party):
Elusys Therapeutics Identifier:
First received: October 14, 2011
Last updated: May 22, 2013
Last verified: October 2011
This study will determine the safety and PK of a single IV dose of ETI-204 in subjects 18 to 65 years of age. Three cohorts will be studied with subjects receiving ETI-204. This study will be randomized, double-blind and stratified by gender. Each cohort will contain 36 subjects (including at least four females), 30 who will receive ETI-204 and six who will receive placebo.

Condition Intervention Phase
Drug: ETI-204, "Anthim"
Drug: placebo
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Single Dose, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of ETI-204 in Healthy Subjects

Resource links provided by NLM:

Further study details as provided by Elusys Therapeutics:

Primary Outcome Measures:
  • Primary Objective [ Time Frame: 71 days ]
    To evaluate the safety of increasing doses of ETI-204 in healthy subjects

Secondary Outcome Measures:
  • Secondary Objective [ Time Frame: 71 days ]

    To evaluate the PK of increasing singles doses of ETI-204 in healthy subjects.

    To evaluate the immunogenicity of ETI-204 following IV administration in healthy subjects.

Enrollment: 108
Study Start Date: October 2011
Study Completion Date: December 2012
Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ETI-204
ETI-204, Anthim
Drug: ETI-204, "Anthim"
intravenously, single dose
Other Name: ETI-204
Sham Comparator: placebo Drug: placebo
intravenously, single dose

Detailed Description:

Protocol AH-105 is a single center, randomized, double-blind, placebo-controlled, sequential, dose escalation study. It will evaluate the safety and PK of single IV doses of ETI-204 administered to approximately 108 healthy male and female subjects. At each dose level, 30 healthy subjects, including at least 4 females, will be randomly assigned to active drug, and at least 6 healthy subjects of both genders will be randomly assigned to matching placebo.

Description of Agent: ETI-204 is a monoclonal antibody (mAb) to protective antigen (PA) from Bacillus anthracis.

The study will consist of 3 phases: Screening, Inpatient, and Outpatient Follow-up. Enrollment criteria will be determined during the 21-day Screening Phase (Visit 1), following by a 3 night inpatient phase where eligible subjects will receive a single dose of IV ETI-204 or matching placebo as described above and undergo routine safety monitoring, dermatologic assessments, and blood draws at pre-specified time points. Subjects will be discharged from the center after collection of the 48-hour PK sample. During the subsequent 70-day outpatient follow-up phase, subjects will return to the center on Days 8, 15, 29, 43 and 71 for clinical laboratory testing (hematology and clinical chemistry), physical examinations and vital signs measurements, and routine safety monitoring. Blood samples for PK and anti-drug antibodies (ADA)will also be collected. The 70 day post-dosing follow-up in this study was selected to allow characterization for the PK profile of ETI-204 and the potential development of ADA.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria: Subjects who meet all of the criteria shown below may be included in the study.

  1. Healthy male or female subjects between 18 and 65 years of age.
  2. Subjects with a body mass index (BMI) > 18.5 and < 35 kg/m2.
  3. Female subjects of childbearing potential (not post-menopausal or surgically sterile) must have a negative urine β-hCG pregnancy test at Screening.
  4. Female subjects of childbearing potential (not post-menopausal or surgically sterile) must use a medically accepted method of contraception for the duration of the study, including the 70-day follow-up period. Acceptable methods of contraception include abstinence, a barrier method with spermicide, an intrauterine device (IUD) or a hormonal contraceptive (oral, transdermal, implanted, or injected) in conjunction with a barrier method.
  5. Male subjects must agree to practice abstinence or to use a condom with spermicide for the duration of the study, including the 70-day follow-up period.
  6. The subject has no clinically significant abnormalities on the clinical laboratory tests (hematology, clinical chemistry, or urinalysis) or ECG at Screening.
  7. Subject provides written informed consent.

Exclusion Criteria:Subjects who meet any of the criteria below will be excluded from participation in the study.

  1. Subject requires regular use of a medication for a chronic condition.
  2. Subject has a clinically significant comorbidity that would interfere with the completion of the study procedures or objectives, or would compromise the subject's safety.
  3. Subject has a systolic blood pressure (BP) > 140 mm Hg or a diastolic BP > 90 mm Hg.
  4. Subject has a systolic BP < 90 mm Hg.
  5. Subject has current suspected drug or alcohol abuse as specified in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) (American Psychiatric Association 2000).
  6. Subject has a positive alcohol or drug test result at Screening and on Day -1
  7. Subject has received an investigational agent within 30 days or 5 half-lives (whichever is longer) of Screening.
  8. Subject has congenital or acquired immunodeficiency syndrome.
  9. Subject has a positive test for Hepatitis B (surface antigen), Hepatitis C, or human immunodeficiency virus (HIV) at Screening.
  10. Subject smokes > 3 cigarettes per day.
  11. Subject has ever had prior treatment for anthrax exposure, prior anthrax infection, prior immunization with any anthrax vaccine or prior treatment with an investigational anthrax treatment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01453907

United States, Kansas
Overland Park, Kansas, United States, 66211
Sponsors and Collaborators
Elusys Therapeutics
Principal Investigator: Eleanor A Lisbon, M.D., M.P.H Quintiles Phase One Services
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Elusys Therapeutics Identifier: NCT01453907     History of Changes
Other Study ID Numbers: AH105
Study First Received: October 14, 2011
Last Updated: May 22, 2013

Additional relevant MeSH terms:
Bacillaceae Infections
Gram-Positive Bacterial Infections
Bacterial Infections processed this record on April 25, 2017